Literature DB >> 15863810

Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels.

Rikus Knegtering1, Pepijn Baselmans, Stynke Castelein, Fokko Bosker, Richard Bruggeman, Robert J van den Bosch.   

Abstract

OBJECTIVE: The atypical antipsychotic risperidone significantly raises plasma prolactin levels in patients, but clozapine, olanzapine, and quetiapine do not. The differences in neuroendocrine response may be connected with the metabolism of the medications. The authors examined the contributory role of risperidone's active metabolite 9-hydroxy-risperidone by measuring plasma concentrations of risperidone, 9-hydroxy-risperidone, and prolactin.
METHOD: Blood samples taken from 25 patients with psychotic disorders following 6 weeks of treatment with risperidone (mean dose=3 mg/day) were examined. Mean plasma concentrations of risperidone, 9-hydroxy-risperidone, and prolactin were 4.6, 19.4, and 49.3 ng/ml, respectively.
RESULTS: The oral dose of risperidone correlated significantly with plasma concentrations of risperidone, 9-hydroxy-risperidone, active moiety, and prolactin. The plasma concentration of 9-hydroxy-risperidone, but not of risperidone, correlated significantly with increases in plasma prolactin.
CONCLUSIONS: These data suggest that the 9-hydroxy metabolite plays a predominant role in risperidone's effect on prolactin release.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863810     DOI: 10.1176/appi.ajp.162.5.1010

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  31 in total

Review 1.  The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings.

Authors:  Marrit K de Boer; Stynke Castelein; Durk Wiersma; Robert A Schoevers; Henderikus Knegtering
Journal:  Schizophr Bull       Date:  2015-02-25       Impact factor: 9.306

2.  In vitro and in vivo demonstration of risperidone implants in mice.

Authors:  C Rabin; Y Liang; R S Ehrlichman; A Budhian; K L Metzger; C Majewski-Tiedeken; K I Winey; S J Siegel
Journal:  Schizophr Res       Date:  2007-08-31       Impact factor: 4.939

Review 3.  Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.

Authors:  Jeffrey Rado; Philip G Janicak
Journal:  Drugs Aging       Date:  2012-10       Impact factor: 3.923

4.  Impact of the CYP2D6 phenotype on hyperprolactinemia development as an adverse event of treatment with atypical antipsychotic agents in pediatric patients.

Authors:  Raluca Grădinaru; Nicoleta Andreescu; Laura Nussbaum; Liana Suciu; Maria Puiu
Journal:  Ir J Med Sci       Date:  2019-02-15       Impact factor: 1.568

5.  In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study.

Authors:  S E Holmes; R Hinz; R J Drake; C J Gregory; S Conen; J C Matthews; J M Anton-Rodriguez; A Gerhard; P S Talbot
Journal:  Mol Psychiatry       Date:  2016-10-04       Impact factor: 15.992

Review 6.  Paliperidone extended release: in adolescents with schizophrenia.

Authors:  Caroline M Perry
Journal:  Paediatr Drugs       Date:  2012-12-01       Impact factor: 3.022

7.  Genetics-Based Population Pharmacokinetics and Pharmacodynamics of Risperidone in a Psychiatric Cohort.

Authors:  Frederik Vandenberghe; Monia Guidi; Eva Choong; Armin von Gunten; Philippe Conus; Chantal Csajka; Chin B Eap
Journal:  Clin Pharmacokinet       Date:  2015-12       Impact factor: 6.447

Review 8.  Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.

Authors:  Silvio Caccia
Journal:  Paediatr Drugs       Date:  2013-06       Impact factor: 3.022

Review 9.  Paliperidone: a review of clinical trial data and clinical implications.

Authors:  Sheng-Min Wang; Changsu Han; Soo-Jung Lee; Ashwin A Patkar; Chi-Un Pae; W Wolfgang Fleischhacker
Journal:  Clin Drug Investig       Date:  2012-08-01       Impact factor: 2.859

10.  Paliperidone ER: a review of the clinical trial data.

Authors:  Philip G Janicak; Elizabeth A Winans
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.